B2B Biopack ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  14.8% 5.9% 10.3% 26.0% 14.0%  
Credit score (0-100)  15 39 22 2 15  
Credit rating  BB BBB BB B BB  
Credit limit (kDKK)  0.0 0.0 0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -106 -271 -412 -1,408 -398  
EBITDA  -108 -271 -412 -1,408 -398  
EBIT  -108 -271 -412 -1,408 -398  
Pre-tax profit (PTP)  -108.7 -275.1 -455.2 -1,555.0 -653.7  
Net earnings  -108.7 -275.1 -455.2 -1,555.0 -656.7  
Pre-tax profit without non-rec. items  -109 -275 -455 -1,555 -654  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  1,239 964 509 -1,046 -1,702  
Interest-bearing liabilities  50.0 875 470 1,050 1,797  
Balance sheet total (assets)  1,451 2,264 2,626 4,272 3,604  

Net Debt  31.9 863 465 1,036 1,790  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -106 -271 -412 -1,408 -398  
Gross profit growth  65.1% -156.1% -52.3% -241.4% 71.7%  
Employees  1 0 0 2 2  
Employee growth %  0.0% -100.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,451 2,264 2,626 4,272 3,604  
Balance sheet change%  673.6% 56.0% 16.0% 62.7% -15.6%  
Added value  -107.7 -270.9 -412.4 -1,408.0 -398.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 65 -11  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -2.0 -3.0 -4.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  101.8% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -11.4% -14.6% -16.9% -35.4% -7.5%  
ROI %  -12.5% -17.3% -29.3% -138.8% -28.0%  
ROE %  -15.2% -25.0% -61.8% -65.0% -16.7%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  85.4% 42.6% 19.4% -19.7% -32.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -29.7% -318.6% -112.7% -73.6% -449.5%  
Gearing %  4.0% 90.7% 92.3% -100.4% -105.5%  
Net interest  0 0 0 0 0  
Financing costs %  0.4% 0.9% 6.4% 19.3% 18.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.8 0.3 0.2 0.1 0.1  
Current Ratio  6.9 1.7 1.6 0.8 0.7  
Cash and cash equivalent  18.1 12.1 5.0 14.0 6.4  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,239.4 899.6 914.3 -1,111.0 -1,756.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -108 0 0 -704 -199  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -108 0 0 -704 -199  
EBIT / employee  -108 0 0 -704 -199  
Net earnings / employee  -109 0 0 -778 -328